Journal article
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)
The Lancet (British edition), Vol.385(9972), pp.977-1010
03/14/2015
DOI: 10.1016/S0140-6736(14)62038-9
PMCID: PMC4588097
PMID: 25467588
Abstract
Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control.
Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75,000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights.
5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease.
International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems.
Canadian Partnership Against Cancer (Toronto, Canada), Cancer Focus Northern Ireland (Belfast, UK), Cancer Institute New South Wales (Sydney, Australia), Cancer Research UK (London, UK), Centers for Disease Control and Prevention (Atlanta, GA, USA), Swiss Re (London, UK), Swiss Cancer Research foundation (Bern, Switzerland), Swiss Cancer League (Bern, Switzerland), and University of Kentucky (Lexington, KY, USA).
Details
- Title: Subtitle
- Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)
- Creators
- Claudia Allemani - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UKHannah K Weir - Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USAHelena Carreira - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UKRhea Harewood - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UKDevon Spika - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UKXiao-Si Wang - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UKFinian Bannon - Northern Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast, Belfast, UKJane V Ahn - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UKChristopher J Johnson - Cancer Data Registry of Idaho, Boise, ID, USAAudrey Bonaventure - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UKRafael Marcos-Gragera - Unitat d'Epidemiologia i Registre de Càncer de Girona, Departament de Salut, Institut d'Investigació Biomèdica de Girona, Girona, SpainCharles Stiller - South East Knowledge and Intelligence Team, Public Health England, Oxford, UKGulnar Azevedo e Silva - Department of Epidemiology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, BrazilWan-Qing Chen - National Office for Cancer Prevention and Control and National Central Cancer Registry, National Cancer Center, Beijing, ChinaOlufemi J Ogunbiyi - Ibadan Cancer Registry, University City College Hospital, Ibadan, NigeriaBernard Rachet - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UKMatthew J Soeberg - New South Wales Central Cancer Registry, Australian Technology Park, Sydney, NSW, AustraliaHui You - Cancer Institute NSW, Sydney, NSW, AustraliaTomohiro Matsuda - Population-Based Cancer Registry Section, Division of Surveillance, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, JapanMagdalena Bielska-Lasota - Department of Health Promotion and Postgraduate Education, National Institute of Public Health and National Institute of Hygiene, Warsaw, PolandHans Storm - Cancer Prevention and Documentation, Danish Cancer Society, Copenhagen, DenmarkThomas C Tucker - Kentucky Cancer Registry, University of Kentucky, Lexington, KY, USAMichel P Coleman - Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: concord@lshtm.ac.ukCONCORD Working Group
- Contributors
- C. F Lynch (Contributor) - University of Iowa, Epidemiology
- Resource Type
- Journal article
- Publication Details
- The Lancet (British edition), Vol.385(9972), pp.977-1010
- DOI
- 10.1016/S0140-6736(14)62038-9
- PMID
- 25467588
- PMCID
- PMC4588097
- ISSN
- 0140-6736
- eISSN
- 1474-547X
- Grant note
- 12FED03123 / PHS HHS ACO12036 / PHS HHS C1336/A16148 / Cancer Research UK P30 CA177558 / NCI NIH HHS CC999999 / Intramural CDC HHS
- Language
- English
- Date published
- 03/14/2015
- Academic Unit
- Epidemiology
- Record Identifier
- 9984213370702771
Metrics
5 Record Views